- Release of [OncoKB™ SOP v5.1](https://sop.oncokb.org/)
- Update to OncoKB’s gene classification system to include a new category, “Insufficient Evidence,” for genes with weak or conflicting evidence describing their role as oncogenes or tumor suppressor genes. For more details, please refer to the OncoKB™ SOP v5.1.

**Updated Therapeutic Implications**

- New alteration(s) with a tumor type-specific level of evidence

| Level | Gene | Mutation                                                                                                                                                                                                                             | Cancer Type                | Drug(s) Added to OncoKB™          | Evidence                                                                                                                                                                                                                                                                                                                         |
| :---- | :--- | :----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | :------------------------- | :-------------------------------- | :------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| 1     | EGFR | Oncogenic Mutations (excluding L858R, Exon 19 deletions, T790M, G719, L861Q, S768I, Exon 20 in-frame insertions, G724S, L718Q/V, D761Y, Exon 19 in-frame insertions, L747P and Kinase Domain Duplication, which are already leveled) | Non-Small Cell Lung Cancer | Datopotamab Deruxtecan (Level 1\) | [FDA approval of datopotamab deruxtecan](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-datopotamab-deruxtecan-dlnk-egfr-mutated-non-small-cell-lung-cancer); PMID: [39761483](https://pubmed.ncbi.nlm.nih.gov/39761483/), [39250535](https://pubmed.ncbi.nlm.nih.gov/39250535/) |

- Promotion of tumor type-specific level of evidence for an alteration

| Gene | Mutation                    | Cancer Type                | Level-associated Drug(s) in OncoKB™                                                                                                                                                | Previous Level | Updated Level | Evidence                                                                                                                                                                                                                                                                                                                         |
| :--- | :-------------------------- | :------------------------- | :--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | :------------- | :------------ | :------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| EGFR | G724S, L718Q/V              | Non-Small Cell Lung Cancer | _Drug(s) added to OncoKB™:_ Datopotamab Deruxtecan (Level 1\)<br/><br/>_Drug(s) remaining in OncoKB™:_ Afatinib (Level 3A)                                                         | 3A             | 1             | [FDA approval of datopotamab deruxtecan](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-datopotamab-deruxtecan-dlnk-egfr-mutated-non-small-cell-lung-cancer); PMID: [39761483](https://pubmed.ncbi.nlm.nih.gov/39761483/), [39250535](https://pubmed.ncbi.nlm.nih.gov/39250535/) |
| EGFR | Exon 19 in-frame insertions | Non-Small Cell Lung Cancer | _Drug(s) added to OncoKB™:_ Datopotamab Deruxtecan (Level 1\)<br/><br/>_Drug(s) remaining in OncoKB™:_ Erlotinib, Gefitinib, Patritumab Deruxtecan (Level 3A), Afatinib (Level 4\) | 3A             | 1             | [FDA approval of datopotamab deruxtecan](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-datopotamab-deruxtecan-dlnk-egfr-mutated-non-small-cell-lung-cancer); PMID: [39761483](https://pubmed.ncbi.nlm.nih.gov/39761483/), [39250535](https://pubmed.ncbi.nlm.nih.gov/39250535/) |
| EGFR | Kinase Domain Duplication   | Non-Small Cell Lung Cancer | _Drug(s) added to OncoKB™:_ Datopotamab Deruxtecan (Level 1\)<br/><br/>_Drug(s) remaining in OncoKB™:_ Afatinib, Erlotinib (Level 3A), Gefitinib (Level 4\)                        | 3A             | 1             | [FDA approval of datopotamab deruxtecan](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-datopotamab-deruxtecan-dlnk-egfr-mutated-non-small-cell-lung-cancer); PMID: [39761483](https://pubmed.ncbi.nlm.nih.gov/39761483/), [39250535](https://pubmed.ncbi.nlm.nih.gov/39250535/) |
| EGFR | L747P                       | Non-Small Cell Lung Cancer | _Drug(s) added to OncoKB™:_ Datopotamab Deruxtecan (Level 1\)<br/><br/>_Drug(s) remaining in OncoKB™:_ Afatinib (Level 4\)                                                         | 4              | 1             | [FDA approval of datopotamab deruxtecan](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-datopotamab-deruxtecan-dlnk-egfr-mutated-non-small-cell-lung-cancer); PMID: [39761483](https://pubmed.ncbi.nlm.nih.gov/39761483/), [39250535](https://pubmed.ncbi.nlm.nih.gov/39250535/) |
| EGFR | D761Y                       | Non-Small Cell Lung Cancer | _Drug(s) added to OncoKB™:_ Datopotamab Deruxtecan (Level 1\)<br/><br/>_Drug(s) remaining in OncoKB™:_ Osimertinib (Level 4\)                                                      | 4              | 1             | [FDA approval of datopotamab deruxtecan](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-datopotamab-deruxtecan-dlnk-egfr-mutated-non-small-cell-lung-cancer); PMID: [39761483](https://pubmed.ncbi.nlm.nih.gov/39761483/), [39250535](https://pubmed.ncbi.nlm.nih.gov/39250535/) |

- Addition of drug(s) associated with a tumor type-specific leveled alteration(s) currently in OncoKB™ (without changing the alteration's highest level of evidence)

| Level | Gene | Mutation                          | Cancer Type                | Level-Associated Drug(s) in OncoKB™                                                                                                                                         | Drug(s) Added to OncoKB™                         | Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| :---- | :--- | :-------------------------------- | :------------------------- | :-------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | :----------------------------------------------- | :--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| 1     | EGFR | Exon 20 in-frame insertions       | Non-Small Cell Lung Cancer | Amivantamab, Amivantamab \+ Chemotherapy (Level 1\)                                                                                                                         | Datopotamab Deruxtecan, Sunvozertinib (Level 1\) | [FDA approval of datopotamab deruxtecan](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-datopotamab-deruxtecan-dlnk-egfr-mutated-non-small-cell-lung-cancer); PMID: [39761483](https://pubmed.ncbi.nlm.nih.gov/39761483/), [39250535](https://pubmed.ncbi.nlm.nih.gov/39250535/); [FDA approval of sunvozertinib](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sunvozertinib-metastatic-non-small-cell-lung-cancer-egfr-exon-20); Abstract: [Yang, JCH. et al., ASCO 2024](https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.8513) |
| 1     | EGFR | Exon 19 in-frame deletions, L858R | Non-Small Cell Lung Cancer | Amivantamab \+ Chemo, Erlotinib, Gefitinib, Dacomitinib, Afatinib, Osimertinib, Lazertinib \+ Amivantamab, Erlotinib \+ Ramucirumab, Osimertinib \+ Chemotherapy (Level 1\) | Datopotamab Deruxtecan (Level 1\)                | [FDA approval of datopotamab deruxtecan](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-datopotamab-deruxtecan-dlnk-egfr-mutated-non-small-cell-lung-cancer); PMID: [39761483](https://pubmed.ncbi.nlm.nih.gov/39761483/), [39250535](https://pubmed.ncbi.nlm.nih.gov/39250535/)                                                                                                                                                                                                                                                                                                         |
| 1     | EGFR | G719, L861Q, S768I                | Non-Small Cell Lung Cancer | Afatinib (Level 1\)                                                                                                                                                         | Datopotamab Deruxtecan (Level 1\)                | [FDA approval of datopotamab deruxtecan](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-datopotamab-deruxtecan-dlnk-egfr-mutated-non-small-cell-lung-cancer); PMID: [39761483](https://pubmed.ncbi.nlm.nih.gov/39761483/), [39250535](https://pubmed.ncbi.nlm.nih.gov/39250535/)                                                                                                                                                                                                                                                                                                         |
| 1     | EGFR | T790M                             | Non-Small Cell Lung Cancer | Osimertinib (Level 1\)                                                                                                                                                      | Datopotamab Deruxtecan (Level 1\)                | [FDA approval of datopotamab deruxtecan](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-datopotamab-deruxtecan-dlnk-egfr-mutated-non-small-cell-lung-cancer); PMID: [39761483](https://pubmed.ncbi.nlm.nih.gov/39761483/), [39250535](https://pubmed.ncbi.nlm.nih.gov/39250535/)                                                                                                                                                                                                                                                                                                         |

- Addition of 2 new genes:
  - ABCC3
  - PAK3
